Livia Adams Goldraich

Livia Adams Goldraich

Auto-generated profile, based on publicly available information

Livia Adams Goldraich

Heart Transplant Program, Division of Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
LMLídia Ana Zytynski Moura
Lídia Ana Zytynski Moura
VIVictor Sarli Issa
Victor Sarli Issa
JVJefferson Luis Vieira
Jefferson Luis Vieira
LRLuis Eduardo Rohde
Luis Eduardo Rohde
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
Introdução A última Diretriz de Insuficiência Cardíaca do Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC/SBC) foi finalizada em março de 2018. A partir de então, houve um importante número de intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional e na pesquisa clínica. Ao lado disso, a pandemia da COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico da agressão miocárdica e muitas dúvidas acerca da continuidade e da segurança dos medicamentos nos pacientes [...] Introdução A última Diretriz de Insuficiência Cardíaca do Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC/SBC) foi finalizada em março de 2018. A partir de então, houve um importante número de intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional e na pesquisa clínica. Ao lado disso, a pandemia da COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico da agressão miocárdica e muitas dúvidas acerca da continuidade e da segurança dos medicamentos nos pacientes

31 August 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
LGLivia Adams Goldraich
Livia Adams Goldraich
Santiago Alonso Tobar LeitãoSantiago Alonso Tobar Leitão
Santiago Alonso Tobar Leitão
FSFernando Luis Scolari
Fernando Luis Scolari
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
MBMarcely Gimenes Bonatto
Marcely Gimenes Bonatto
NCNadine Clausell
Nadine Clausell
: Heart transplantation is the standard of therapy for patients with end-stage heart disease. Since the first human-to-human heart transplantation, performed in 1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically increased recipient survival. However, there are yet many challenges in the modern era of heart transplantation in which immunosuppression may play a key role in further advances in the field. A fine-tuning of immune modulation to prevent graft rejection while avoiding side effects from over immunosuppression has been the vital goal of basic and clinical research. Individualization of drug choices and strategies, taking into account the recipient's clinical characteristics, underlying heart failure diagnosis, immunologic risk and comorbidities seem to be the ideal approaches to improve post-transplant morbidity and survival while preventing both rejection and complications of immunosuppression. : The aim of the present review is to provide a practical, comprehensive overview of contemporary immunosuppression in heart transplantation. Clinical evidence for immunosuppressive drugs is reviewed and practical approaches are provided. Cardiac allograft rejection classification and up-to-date management are summarized. Expanding therapies, such as photophoresis, are outlined. Drug-to-drug interactions of immunosuppressive agents focused on cardiovascular medications are summarized. Special situations involving heart transplantation such as sarcoidosis, Chagas diseases and pediatric immunosuppression are also reviewed. The evolution of phamacogenomics to individualize immunosuppressive therapy is described. Finally, future perspectives in the field of immunosuppression in heart transplantation are highlighted.

23 November 2017 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
YMYasbanoo Moayedi
Yasbanoo Moayedi
JPJuan G. Duero Posada
Juan G. Duero Posada
FFFarid Foroutan
Farid Foroutan
LGLivia A. Goldraich
Livia A. Goldraich
AAAna Alba-Rubio
Ana Alba-Rubio
HRHeather J. Ross
Heather J. Ross

1 January 2013 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PZPriccila Zuchinali
Priccila Zuchinali
GSGabriela Correa Souza
Gabriela Correa Souza
FAFernanda Donner Alves
Fernanda Donner Alves
KDKarina Sanches Machado D'Almeida
Karina Sanches Machado D'Almeida
LGLívia Adams Goldraich
Lívia Adams Goldraich
LRLuis Eduardo Paim Rohde
Luis Eduardo Paim Rohde
Most reports regarding the obesity paradox have focused on body mass index (BMI) to classify obesity and the prognostic values of other indirect measurements of body composition remain poorly examined in heart failure (HF). To evaluate the association between BMI and other indirect, but easily accessible, body composition measurements associated with the risk of all-cause mortality in HF. Anthropometric parameters of body composition were assessed in 344 outpatients with a left ventricular ejection fraction (LVEF) of 20 mm was present in 9% of patients that died and 22% of those who survived (p = 0.027). Univariate analysis showed that serum creatinine level, LVEF, and NYHA class were associated with the risk of death, while Cox proportional hazard regression analysis showed that TSF > 20 was a strong independent predictor of all-cause mortality (hazard ratio = 0.36; 95% confidence interval = 0.13-0.97, p = 0.03). Although BMI is the most widely used anthropometric parameter in clinical practice, our results suggested that TSF is a better predictive marker of mortality in HF outpatients.

28 June 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
LGLivia A. Goldraich
Livia A. Goldraich
JSJosef Stehlik
Josef Stehlik
WCWida S. Cherikh
Wida S. Cherikh
LELeah B. Edwards
Leah B. Edwards
RURead Urban
Read Urban
HRHeather J. Ross
Heather J. Ross

29 July 2023 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
DNDaniela Meirelles Do Nascimento
Daniela Meirelles Do Nascimento
KMKarina Costa Machado
Karina Costa Machado
PBPatricia Martins Bock
Patricia Martins Bock
MSMarco Aurélio Lumertz Saffi
Marco Aurélio Lumertz Saffi
LGLivia Adams Goldraich
Livia Adams Goldraich
BSBeatriz Schaan
Beatriz Schaan
Background: Functional training may be an effective non-pharmacological therapy for heart failure (HF). This study aimed to compare the effects of functional training with strength training on peak VO2 and quality of life in individuals with HF. Methods: A randomized, parallel-design and examiner-blinded controlled clinical trial with concealed allocation, intention-to-treat and per-protocol analyses. Twenty-seven participants with chronic HF were randomly allocated to functional or strength training group, to perform a 12-week physical training, three times per week, totalizing 36 sessions. Primary outcomes were the difference on peak VO2 and quality of life assessed by cardiopulmonary exercise testing and Minnesota Living with Heart Failure Questionnaire, respectively. Secondary outcomes included functionality assessed by the Duke Activity Status Index and gait speed test, peripheral and inspiratory muscular strength, assessed by hand grip and manovacuometry testing, respectively, endothelial function by brachial artery flow-mediated dilation, and lean body mass by arm muscle circumference. Results: Participants were aged 60 ± 7 years, with left ventricular ejection fraction 29 ± 8.5%. The functional and strength training groups showed the following results, respectively: peak VO2 increased by 1.4 ± 3.2 (16.9 ± 2.9 to 18.6 ± 4.8 mL.kg−1.min−1; p time = 0.011) and 1.5 ± 2.5 mL.kg−1.min−1 (16.8 ± 4.0 to 18.6 ± 5.5 mL.kg−1.min−1; p time = 0.011), and quality of life score decreased by 14 ± 15 (25.8 ± 14.8 to 10.3 ± 7.8 points; p time = 0.001) and 12 ± 28 points (33.8 ± 23.8 to 19.0 ± 15.1 points; p time = 0.001), but no difference was observed between groups (peak VO2: p interaction = 0.921 and quality of life: p interaction = 0.921). The functional and strength training increased the activity status index by 6.5 ± 12 and 5.2 ± 13 points (p time = 0.001), respectively, and gait speed by 0.2 ± 0.3 m/s (p time = 0.002) in both groups. Conclusions: Functional and strength training are equally effective in improving peak VO2, quality of life, and functionality in individuals with HF. These findings suggest that functional training may be a promising and innovative exercise-based strategy to treat HF. Trial registration: NCT03321682. Registered date: 26/10/2017.